FY2024 Earnings Estimate for Immunic Issued By HC Wainwright

Immunic, Inc. (NASDAQ:IMUX) – HC Wainwright issued their FY2024 earnings estimates for shares of Immunic in a report issued on Monday, November 25th. HC Wainwright analyst M. Caufield anticipates that the company will earn ($0.95) per share for the year. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Immunic’s FY2025 earnings at ($0.85) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at ($0.60) EPS and FY2028 earnings at ($0.23) EPS.

IMUX has been the topic of several other research reports. B. Riley started coverage on shares of Immunic in a research note on Tuesday, August 27th. They set a “buy” rating and a $6.00 price objective on the stock. Leerink Partnrs raised shares of Immunic to a “strong-buy” rating in a research note on Monday, September 9th. Leerink Partners restated an “outperform” rating and set a $5.00 target price on shares of Immunic in a report on Monday, September 9th. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, September 16th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Immunic presently has an average rating of “Buy” and an average target price of $11.80.

Immunic Trading Up 5.3 %

Shares of NASDAQ IMUX opened at $1.20 on Wednesday. The firm has a market capitalization of $108.09 million, a PE ratio of -0.98 and a beta of 1.88. Immunic has a 1 year low of $0.97 and a 1 year high of $2.11. The firm’s 50-day moving average is $1.37 and its 200-day moving average is $1.34.

Insiders Place Their Bets

In other Immunic news, Director Richard Alan Rudick bought 87,300 shares of Immunic stock in a transaction dated Tuesday, November 12th. The stock was bought at an average price of $1.15 per share, with a total value of $100,395.00. Following the completion of the transaction, the director now owns 87,300 shares in the company, valued at $100,395. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IMUX. Virtu Financial LLC acquired a new position in Immunic during the first quarter worth about $25,000. Jane Street Group LLC raised its stake in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares in the last quarter. State Street Corp raised its stake in Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after acquiring an additional 11,642 shares in the last quarter. Finally, Ikarian Capital LLC raised its stake in Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after acquiring an additional 1,162,378 shares in the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.